Dr. John Allan, M.D
NPI: 1144462441
Total Payments
$550,557
2024 Payments
$55,492
Companies
29
Transactions
566
Medicare Patients
2,056
Medicare Billing
$566,779
Payment Breakdown by Category
Other$255,644 (46.4%)
Consulting$220,030 (40.0%)
Travel$47,677 (8.7%)
Research$14,522 (2.6%)
Food & Beverage$12,584 (2.3%)
Education$99.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $248,750 | 89 | 45.2% |
| Consulting Fee | $220,030 | 113 | 40.0% |
| Travel and Lodging | $47,677 | 160 | 8.7% |
| Unspecified | $14,522 | 27 | 2.6% |
| Food and Beverage | $12,584 | 170 | 2.3% |
| Honoraria | $6,894 | 6 | 1.3% |
| Education | $99.99 | 1 | 0.0% |
Payments by Type
General
$536,035
539 transactions
Research
$14,522
27 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| BeiGene USA, Inc. | $184,054 | 132 | $0 (2024) |
| ABBVIE INC. | $96,359 | 137 | $0 (2024) |
| Janssen Biotech, Inc. | $81,018 | 75 | $0 (2023) |
| Pharmacyclics LLC, An AbbVie Company | $52,396 | 81 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $27,560 | 17 | $0 (2024) |
| Janssen Global Services, LLC | $27,134 | 18 | $0 (2024) |
| Genentech USA, Inc. | $16,242 | 21 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $11,861 | 20 | $0 (2024) |
| Lilly USA, LLC | $9,285 | 3 | $0 (2023) |
| Adaptive Biotechnologies Corporation | $6,214 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $55,492 | 71 | ABBVIE INC. ($16,884) |
| 2023 | $157,100 | 129 | BeiGene USA, Inc. ($94,962) |
| 2022 | $131,231 | 114 | BeiGene USA, Inc. ($59,758) |
| 2021 | $93,612 | 74 | Janssen Biotech, Inc. ($18,839) |
| 2020 | $42,799 | 44 | AbbVie Inc. ($14,597) |
| 2019 | $43,130 | 70 | Pharmacyclics LLC, An AbbVie Company ($13,662) |
| 2018 | $16,471 | 27 | Bayer HealthCare Pharmaceuticals Inc. ($5,864) |
| 2017 | $10,723 | 37 | Genentech USA, Inc. ($4,677) |
All Payment Transactions
566 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $412.50 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,500.00 | General |
| Category: Oncology | ||||||
| 12/19/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $412.50 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $412.50 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Oncology | ||||||
| 12/19/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | Cash or cash equivalent | $25.25 | General |
| Category: Oncology | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $5,740.00 | General |
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $968.60 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $546.96 | Research |
| Study: AN OPEN-LABEL, MULTI-CENTER PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC MONOCLONAL ANTIBODY, IN PATIENTS WITH CD20+ B-CELL MALIGNANCIES PREVIOUSLY TREATED WITH CD20-DIRECTED ANTIBODY THERAPY (ELM-1) | ||||||
| 12/08/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $875.03 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 12/07/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $105.35 | General |
| Category: Oncology | ||||||
| 12/07/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $24.29 | General |
| Category: BioOncology | ||||||
| 12/06/2024 | Janssen Global Services, LLC | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $146.36 | General |
| Category: Oncology | ||||||
| 12/06/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $83.45 | General |
| Category: Oncology | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: Oncology | ||||||
| 12/05/2024 | ABBVIE INC. | EPKINLY (Drug) | Consulting Fee | Cash or cash equivalent | $412.50 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,500.00 | General |
| Category: Oncology | ||||||
| 11/25/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Oncology | ||||||
| 11/25/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | Cash or cash equivalent | $25.70 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Eli Lilly and Company | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,600.00 | General |
| Category: Oncology | ||||||
| 11/16/2024 | ABBVIE INC. | EPKINLY (Drug) | Travel and Lodging | In-kind items and services | $506.62 | General |
| Category: ONCOLOGY | ||||||
| 11/16/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: ONCOLOGY | ||||||
| 11/16/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $10.00 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | ABBVIE INC. | EPKINLY (Drug) | Travel and Lodging | In-kind items and services | $288.22 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $481.25 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AN OPEN-LABEL, MULTI-CENTER PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC MONOCLONAL ANTIBODY, IN PATIENTS WITH CD20+ B-CELL MALIGNANCIES PREVIOUSLY TREATED WITH CD20-DIRECTED ANTIBODY THERAPY (ELM-1) | Regeneron Pharmaceuticals, Inc. | $4,769 | 4 |
| PCYC-1142-CA | Pharmacyclics LLC, An AbbVie Company | $2,646 | 6 |
| AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | Regeneron Pharmaceuticals, Inc. | $2,526 | 4 |
| REGN1979-CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $2,373 | 4 |
| REGN1979-Clinical Development Program | Regeneron Pharmaceuticals, Inc. | $2,192 | 8 |
| UTXTGR205 | TG Therapeutics, Inc. | $15.58 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 533 | 1,255 | $536,125 | $124,712 |
| 2022 | 10 | 476 | 1,130 | $413,265 | $114,611 |
| 2021 | 9 | 592 | 1,471 | $448,295 | $189,003 |
| 2020 | 9 | 455 | 1,136 | $360,965 | $138,452 |
Total Patients
2,056
Total Services
4,992
Medicare Billing
$566,779
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 79 | 286 | $157,300 | $35,711 | 22.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 72 | 329 | $115,150 | $35,595 | 30.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 208 | 422 | $179,350 | $33,847 | 18.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 25 | 25 | $17,500 | $3,986 | 22.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 21 | 25 | $16,250 | $3,845 | 23.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 38 | 45 | $11,250 | $3,325 | 29.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 29 | 46 | $11,500 | $3,175 | 27.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 40 | 56 | $16,800 | $2,852 | 17.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 21 | 21 | $11,025 | $2,378 | 21.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 168 | 367 | $142,290 | $28,853 | 20.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 54 | 195 | $97,560 | $24,575 | 25.2% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 40 | 145 | $23,200 | $23,134 | 99.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 56 | 238 | $80,320 | $22,057 | 27.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 33 | 33 | $17,325 | $3,721 | 21.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 18 | 19 | $12,350 | $3,419 | 27.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 48 | 61 | $15,990 | $2,677 | 16.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 16 | 16 | $10,850 | $2,535 | 23.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 29 | 34 | $8,060 | $2,224 | 27.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 14 | 22 | $5,320 | $1,417 | 26.6% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 65 | 428 | $68,480 | $68,841 | 100.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 81 | 248 | $112,840 | $39,602 | 35.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 70 | 270 | $89,100 | $25,619 | 28.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 115 | 189 | $64,260 | $21,068 | 32.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 77 | 106 | $36,040 | $9,838 | 27.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 70 | 85 | $19,550 | $6,794 | 34.8% |
About Dr. John Allan, M.D
Dr. John Allan, M.D is a Student in an Organized Health Care Education/Training Program healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/01/2009. The National Provider Identifier (NPI) number assigned to this provider is 1144462441.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Allan, M.D has received a total of $550,557 in payments from pharmaceutical and medical device companies, with $55,492 received in 2024. These payments were reported across 566 transactions from 29 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($248,750).
As a Medicare-enrolled provider, Allan has provided services to 2,056 Medicare beneficiaries, totaling 4,992 services with total Medicare billing of $566,779. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Hematology & Oncology
- Location New York, NY
- Active Since 04/01/2009
- Last Updated 04/17/2015
- Taxonomy Code 390200000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1144462441
Products in Payments
- BRUKINSA (Drug) $179,429
- IMBRUVICA (Drug) $135,785
- VENCLEXTA (Drug) $45,219
- CALQUENCE (Drug) $23,213
- Imbruvica (Drug) $20,994
- Rituxan (Biological) $10,761
- Venclexta (Drug) $8,892
- VENCLEXTA (Biological) $7,224
- clonoSEQ (Device) $6,092
- Aliqopa (Drug) $5,864
- TAZVERIK (Drug) $4,894
- JAYPIRCA (Drug) $4,400
- Ibrutinib (Drug) $2,646
- EPKINLY (Drug) $1,322
- ELREXFIO (Drug) $148.47
- UKONIQ (Drug) $135.88
- Epkinly (Drug) $132.44
- Monoferric (Drug) $124.98
- VERZENIO (Drug) $84.85
- Copiktra (Drug) $77.52
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in New York
Dr. Saakshi Khattri, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $1.7M
Student in an Organized Health Care Education/Training Program $1.7M
Cheguevara Afaneh, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $1.5M
Student in an Organized Health Care Education/Training Program $1.5M
Jose Scher, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $496,980
Student in an Organized Health Care Education/Training Program $496,980
Dr. Anthony Rossi, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $442,377
Student in an Organized Health Care Education/Training Program $442,377
Anuradha Lala-Trindade
Student in an Organized Health Care Education/Training Program — Payments: $284,341
Student in an Organized Health Care Education/Training Program $284,341
Dr. Daniel Han, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $225,630
Student in an Organized Health Care Education/Training Program $225,630